Aligos Therapeutics (ALGS) Income from Continuing Operations (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Income from Continuing Operations came in at 23040000.0 in Q1 2026, down 153.47% YoY from 43088000.0 in Q1 2025, and down 15.89% on a QoQ basis from 19881000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Income from Continuing Operations data on file, last reported at 23040000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 153.47% year-over-year to 23040000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90321000.0 (down 69.59% YoY) and the FY2025 annual result came in at 24193000.0, up 81.56% from the prior year.
- Income from Continuing Operations fell to 23040000.0 in Q1 2026, from 19881000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 43088000.0 in Q1 2025 to a low of 82150000.0 in Q4 2024.
- A 5-year average of 21304058.82 and a median of 19924000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 223.59% in 2025, down 413.44% in 2025.
- Tracing ALGS's Income from Continuing Operations over 5 years: stood at 21886000.0 in 2022, then retreated by 27.44% to 27892000.0 in 2023, then tumbled by 194.53% to 82150000.0 in 2024, then surged by 75.8% to 19881000.0 in 2025, then slipped by 15.89% to 23040000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 23040000.0 (Q1 2026), 19881000.0 (Q4 2025), and 31537000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | -1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Mn |
| Mar 31, 2026 | -23.04 Mn |
| Dec 31, 2025 | -19.88 Mn |
| Sep 30, 2025 | -31.54 Mn |
| Jun 30, 2025 | -15.86 Mn |
| Mar 31, 2025 | 43.09 Mn |
| Dec 31, 2024 | -82.15 Mn |
| Sep 30, 2024 | -19.26 Mn |
| Jun 30, 2024 | 5.06 Mn |
| Mar 31, 2024 | -34.86 Mn |
| Dec 31, 2023 | -27.89 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -18.79 Mn |
| Mar 31, 2023 | -22.96 Mn |
| Dec 31, 2022 | -21.89 Mn |
| Sep 30, 2022 | -18.62 Mn |
| Jun 30, 2022 | -19.92 Mn |
| Mar 31, 2022 | -35.62 Mn |
| Dec 31, 2021 | -37.71 Mn |
| Sep 30, 2021 | -33.12 Mn |